查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371962

全球抗生素抗藥性市場，到 2030 年的預測：按疾病、病原體、藥物類別、作用方式、最終用戶和地區進行的全球分析

Antibiotic Resistance Market Forecasts to 2030 - Global Analysis By Disease, Pathogen, Drug Class, Mechanism of Action, End User and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球抗生素抗藥性市場規模為 87.5 億美元，預計預測期內年複合成長率為 7.7%，到 2030 年將達到 147.1 億美元。

常用於治療各種感染疾病的藥物稱為抗生素。當細菌經歷基因變化或突變，使它們在接觸抗生素時能夠生存和繁殖，從而使藥物效果降低或完全消除時，就會出現抗生素抗藥性。因此，這些抗藥性細菌引起的感染疾病可能難以治療、延長病情、增加治療成本並增加死亡率。

據CDC稱，美國抗生素抗藥性感染疾病的發生率超過280萬人，該疾病年度給該國帶來的負擔估計在210億美元至340億美元之間。在全球範圍內，MRSA 造成了巨大的成本負擔，因為已開發國家的抗藥性平均為 25.0%，開發中國家約為​​ 40%。

抗生素抗藥性感染疾病的患病不斷增加

抗生素抗藥性感染疾病的增加是抗生素抗藥性市場的關鍵促進因素。抗生素的過度使用和濫用導致抗藥性細菌的出現，使得傳統抗生素的效果降低。抗藥性細菌的增加對公眾健康構成嚴重威脅，導致長期患病、死亡率增加和醫療費用增加。由抗生素抗藥性細菌引起的感染疾病通常需要使用較昂貴且可能效果較差的二線治療。因此，對創新抗生素和替代療法來對抗這些抗藥性病原體的需求不斷成長。開發新型有效抗生素的需求正在推動製藥和醫療保健領域的研發工作、吸引投資並促進合作研究。這些要素正在要素市場成長。

嚴格的法規標準

抗生素抗藥性市場面臨嚴格的法規要求，並對藥物開發和市場開拓構成重大挑戰。法規機構需要廣泛的臨床試驗和完整的安全性和有效性文件，以確保新抗生素的有效性。滿足這些要求需要投入大量時間和資源，通常會導致開發時間更長和成本更高。這些因素都阻礙了市場需求。

新型抗生素的開發

新抗生素的開發代表了抗生素抗藥性市場的重大商機。抗生素抗藥性細菌的增加增加了對能夠有效對抗這些頑強病原體的創新藥物的需求。投資新型抗生素的開發不僅是迫切的醫療需求，也是一個充滿希望的商機。此外，考慮到有效抗生素的潛在市場需求和減輕抗生素抗藥性的社會影響，需要公私夥伴關係和合作來推進抗生素研究，促進創新和開發新抗生素，我們正在創造良好的環境以促進發展和商業化

抗生素的過度使用和濫用

抗生素的過度使用和濫用對抗生素抗藥性市場構成了重大威脅。抗生素的過度處方和不當使用通常是由患者需求、缺乏適當的診斷工具或醫療保健專業人員的處方習慣引起的，會導致抗生素抗藥性菌株的產生。當不必要或不當地使用抗生素時，細菌更有可能產生抗藥性，使其不再有效。這些要素導致市場成長放緩。

COVID-19 的影響

在 COVID-19 患者中，在大流行早期，用於治療繼發性細菌感染的抗生素的使用和需求增加。增加使用可能會導致抗生素抗藥性。此外，公眾、醫療保健專業人員和政治家的認知不斷提高，人們更了解了與抗生素抗藥性相關的風險以及適當和負責任地使用抗生素的必要性。這次大流行提醒人們抗生素管理計劃的價值，這些計劃鼓勵負責任地使用抗生素並幫助對抗抗生素抗藥性疾病。醫療保健系統已優先進行此類配合措施，以確保按需要的時間和數量給藥足夠的抗生素，以阻止抗藥性疾病的傳播。整體而言，疫情對全球市場需求產生了正面影響。

四環素抗生素市場預計將在預測期內成為最大的市場

四環素類藥物預計將佔據最大佔有率。四環素類抗生素是四環素類抗生素的一種；四環素類抗生素是四環素類抗生素的一種。四環素抗生素是一類用於治療多種細菌感染疾病的抗生素，由於抗生素抗藥性菌株的出現而面臨挑戰。此外，醫療保健組織和法規機構正在促進負責任的抗生素使用並實施嚴格的指導方針以遏制抗藥性細菌的傳播。在四環素領域，正在進行的研究和合作為對抗抗生素抗藥性和確保感染疾病的有效治療方法提供了一個有希望的途徑。

醫院和診所領域預計在預測期內年複合成長率最高

預計醫院和診所部門在預測期內將出現良好的成長。抗生素抗藥性市場的醫院和診所部分在管理和應對抗生素抗藥性感染疾病帶來的挑戰方面發揮著重要作用。醫療機構處於診斷和治療患者的第一線，因此面臨抗生素抗藥性的直接影響。這部分包括醫院、診所和其他提供醫療服務的醫療機構。這些環境中的醫療保健專業人員積極參與實施抗菌藥物管理計劃、促進感染預防和控制措施以及最佳化抗生素的使用。此外，醫院和診所還透過監測流行病和抗生素抗藥性模式，並與研究人員和法規機構合作制定應對這項全球健康威脅的策略，為監測工作做出貢獻。

比最大的地區

由於該地區感染疾病高發生率而廣泛使用抗生素，亞太地區在估計期間佔據了最大的市場佔有率。亞太地區是全球最大的抗生素使用地區，有可能出現抗生素抗藥性疾病。抗生素抗藥性細菌的出現和傳播是由於不當使用（包括過度使用和濫用抗生素）造成的。此外，亞太地區人口稠密，抗生素抗藥性疾病負擔負擔，使其成為抗藥性細菌擴散的中心。人們對抗生素抗藥性的認知不斷提高，以及對有效干涉措施的需求正在推動該地區解決這一問題的配合措施。

複合年複合成長率最高的地區

預計北美在預測期內將實現盈利成長。北美地區抗生素抗藥性患病很高，據報導抗生素抗藥性感染疾病負擔很大。這是由於醫療機構和社區過度使用和濫用抗生素等要素造成的。該地區也表現出強大的研發活動，重點是開發新的抗生素和替代治療方法。此外，北美的政府配合措施和官民合作關係關係透過實施抗生素管理計畫和提高對適當使用抗生素的認知，在解決抗生素抗藥性方面發揮重要作用。

免費客製化服務：

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究來源
    • 主要研究來源
    • 二次研究來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球抗生素抗藥性市場：依疾病分類

  • 艱難梭菌感染疾病
  • 院內細菌性肺炎
  • 複雜性腹腔內感染疾病
  • 社區型細菌性肺炎
  • 急性細菌性皮膚和皮膚結構感染疾病
  • 血流感染疾病
  • 複雜性尿道感染

第6章 全球抗生素抗藥性市場：依病原體分類

  • 鮑馬尼
  • 銅綠假單胞菌
  • 屎腸球菌
  • 流感嗜血桿菌
  • 肺炎克雷伯菌
  • 大腸桿菌
  • 肺炎鏈球菌
  • 艱難梭菌
  • 金黃色葡萄球菌
  • 鮑氏不動桿菌

第7章 全球抗生素抗藥性市場：依藥物類別

  • 四環素類
  • 頭孢菌素類
  • 噁唑烷酮
  • 聯合治療
  • 胜肽
  • 其他藥物類別

第8章 全球抗生素抗藥性市場：按作用機制

  • 細胞壁合成抑制劑
  • DNA合成抑制劑
  • 蛋白質合成抑制劑
  • RNA合成抑制劑
  • 其他作用機制

第9章 全球抗生素抗藥性市場：依最終用戶分類

  • 醫院/診所
  • 居家護理
  • 研究機構
  • 其他最終用戶

第10章 全球抗生素抗藥性市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第11章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • Basilea Pharmaceutica Ltd.
  • Tetraphase Pharmaceuticals, Inc.
  • Entasis therapeutics
  • Theravance Biopharma
  • Paratek Pharmaceuticals, Inc.
  • Seres Therapeutics
  • Merck & Co. Inc.
  • Achaogen Inc.
  • Melinta Therapeutics
  • AbbVie, Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Cipla Ltd.
  • Bayer AG
  • AstraZeneca plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Roche Holding AG
  • Cubist Pharmaceuticals, Inc.
  • Mylan NV
Product Code: SMRC24019

According to Stratistics MRC, the Global Antibiotic Resistance Market is accounted for $8.75 billion in 2023 and is expected to reach $14.71 billion by 2030 growing at a CAGR of 7.7% during the forecast period. The drugs that are frequently used to treat a variety of infections are referred to as antibiotics. When bacteria endure genetic changes or mutations that allow them to live and grow even when exposed to antibiotics, antibiotic resistance develops, diminishing or completely removing the effectiveness of the drugs. As a result, infections brought on by these resistant bacteria become more challenging to treat, which causes illnesses to last longer, cost more money to treat, and may raise fatality rates.

According to the CDC, the incidence of antibiotic-resistant infections is more than 2.8 million in the U.S. The annual burden of the disease in the country is estimated between USD 21.0 billion to USD 34.0 billion. Globally, MRSA imposes a significant cost burden due to a high resistance rate of an average of 25.0% in developed countries and around 40% in developing regions.

Market Dynamics:

Driver:

Increasing Prevalence of Antibiotic-Resistant Infections

The increasing prevalence of antibiotic-resistant infections is a critical driver of the antibiotic resistance market. Overuse and misuse of antibiotics have led to the emergence of resistant strains of bacteria, rendering conventional antibiotics less effective. This escalating resistance poses a serious threat to public health, resulting in prolonged illnesses, increased mortality rates, and higher healthcare costs. Infections caused by antibiotic-resistant bacteria often necessitate the use of more expensive and potentially less effective second-line treatments. Consequently, there is a growing demand for innovative antibiotics and alternative therapies to combat these resistant pathogens. The need to develop new and effective antibiotics is fueling research and development efforts, attracting investments, and driving collaborations within the pharmaceutical and healthcare sectors. These factors are responsible for market growth.

Restraint:

Stringent regulatory standards

The antibiotic resistance market faces stringent regulatory requirements that can pose significant challenges for drug development and market entry. Regulatory agencies demand extensive clinical trials and thorough documentation of safety and efficacy to ensure the effectiveness of new antibiotics. Meeting these requirements necessitates substantial investments of time and resources, often resulting in prolonged development timelines and increased costs. These elements are hampering market demand.

Opportunity:

Development of novel antibiotics

The development of novel antibiotics presents a significant opportunity within the antibiotic resistance market. With the rise of antibiotic-resistant bacterial strains, there is an emerging need for innovative drugs that can effectively combat these resilient pathogens. Investing in the development of novel antibiotics is not only a healthcare imperative but also a promising business opportunity. Additionally, public-private partnerships and collaborations are fostering a good environment for advancing antibiotic research, encouraging innovation, and expediting the development and commercialization of new antibiotics, driven by the potential market demand for effective antibiotics and the societal impact of mitigating antibiotic resistance.

Threat:

Overuse and Misuse of Antibiotics

Overuse and misuse of antibiotics constitute a significant threat to the antibiotic resistance market. Over-prescription and inappropriate use of antibiotics, often driven by patient demand, a lack of proper diagnostic tools, or medical practitioners' prescribing habits, contribute to the development of antibiotic-resistant strains. When antibiotics are used unnecessarily or incorrectly, bacteria have a higher chance of developing resistance, rendering these drugs ineffective. These factors are responsible for decreasing market growth.

COVID-19 Impact

Antibiotic use and demand increased among COVID-19 patients early in the pandemic to treat secondary bacterial infections. Antibiotic resistance may occur as a result of the increased use. Additionally, there is a better understanding of the risks associated with antibiotic resistance and the necessity for appropriate and responsible antibiotic usage as a result of the increasing awareness among the general public, healthcare professionals, and politicians. The pandemic served as a reminder of the value of antibiotic management programmes, which encourage the responsible use of antibiotics and aid in the fight against antibiotic-resistant illnesses. Healthcare systems gave priority to such initiatives to make sure that antibiotics are only given when necessary and in sufficient quantities to stop the spread of illnesses that are resistant to therapy. Overall, the pandemic had a positive impact on global market demand.

The Tetracyclines segment is expected to be the largest during the forecast period

The Tetracyclines segment is estimated to hold the largest share. This has fuelled the demand for alternative treatment options and the development of novel antibiotics. Tetracyclines, a class of antibiotics used to treat a wide range of bacterial infections, have faced challenges due to the emergence of antibiotic-resistant strains. Additionally, healthcare organisations and regulatory bodies are promoting responsible antibiotic use and implementing stringent guidelines to curb the spread of resistance. While the tetracycline's segment has ongoing research and collaborative efforts hold promise for addressing antibiotic resistance and ensuring effective treatment options for infectious diseases.

The Hospitals & Clinics segment is expected to have the highest CAGR during the forecast period

The Hospitals & Clinics segment is anticipated to have lucrative growth during the forecast period. The hospitals and clinics segment of the antibiotic resistance market plays a crucial role in managing and combating the challenges posed by antibiotic-resistant infections. As healthcare facilities are at the forefront of diagnosing and treating patients, they face the direct impact of antibiotic resistance. This segment encompasses hospitals, clinics, and other healthcare institutions that provide medical services. Healthcare professionals in these settings are actively involved in implementing antimicrobial stewardship programmes, promoting infection prevention and control measures, and optimising the use of antibiotics. Furthermore, hospitals and clinics contribute to surveillance efforts by monitoring the prevalence and patterns of antibiotic resistance and collaborating with researchers and regulatory bodies to develop strategies for combating this global health threat.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to the high prevalence of infectious diseases in the area, extensive antibiotic use has resulted. It represents the greatest user of antibiotics in the world, which raises the possibility of developing diseases with antibiotic resistance. Antibiotic-resistant bacteria have emerged and spread as a result of improper usage of antibiotics, including overuse and misuse. Additionally, the Asia-Pacific area is a hub for the propagation of resistance due to its dense population and high load of diseases that are antibiotic-resistant. The growing awareness about antibiotic resistance and the need for effective interventions are driving efforts to combat the issue in the region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America region has a high prevalence of antibiotic resistance, with a significant burden of antibiotic-resistant infections reported. This is attributed to factors such as the overuse and misuse of antibiotics, both in healthcare settings and in the community. region also exhibits robust research and development activities focused on developing new antibiotics and alternative treatment options. Additionally, government initiatives and public-private partnerships in North America have played a crucial role in addressing antibiotic resistance through the implementation of antibiotic stewardship programmes and raising awareness about appropriate antibiotic use.

Key players in the market

Some of the key players in the Antibiotic Resistance Market include: Basilea Pharmaceutica Ltd., Tetraphase Pharmaceuticals, Inc., Entasis therapeutics, Theravance Biopharma, Paratek Pharmaceuticals, Inc., Seres Therapeutics, Merck & Co. Inc., Achaogen Inc., Melinta Therapeutics, AbbVie, Inc., Johnson & Johnson, Pfizer Inc., Cipla Ltd., Bayer AG, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Roche Holding AG, Cubist Pharmaceuticals, Inc. and Mylan N.V.

Key Developments:

In June 2023, BSI, the business improvement and Standards Company, launched a new global Minimized Risk of Antimicrobial Resistance (AMR) certification designed to promote and attest to the responsible manufacturing of antibiotics in the global supply chain.

In November 2022, Quadripartite launches a new platform to tackle antimicrobial resistance threat to human and animal health and ecosystems. The Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched today to ensure the growing threats and impacts of antimicrobial resistance are addressed globally.

In November 2022, Apollo announced the launch of an Antimicrobial Stewardship Programme (Apollo ASP). The programme will sensitize care providers on Antimicrobial Resistance (AMR), an issue leading to a public health problem.

In April 2022, Johnson & Johnson announced the opening of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the University of Cape Town's Holistic Drug Discovery and Development (H3D).

Diseases Covered:

  • Clostridium difficile infections
  • Hospital-acquired bacterial pneumonia
  • Complicated intra-abdominal infections
  • Community-acquired bacterial pneumonia
  • Acute bacterial skin and skin-structure infection
  • Bloodstream infection
  • Complicated urinary tract infections

Pathogens Covered:

  • Baumannii
  • Pseudomonas aeruginosa
  • Enterococcus faecium
  • Hemophilus Influenzae
  • K. Pneumoniae
  • E. Coli
  • Streptococcus pneumoniae
  • Clostridium difficile
  • Staphylococcus Aureus
  • Acinetobacter

Drug Classes Covered:

  • Tetracyclines
  • Cephalosporins
  • Oxazolidinones
  • Combination therpaies
  • Lipoglycopeptides
  • Other Drug Classes

Mechanism of Actions Covered:

  • Cell Wall Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • RNA synthesis inhibitors
  • Other Mechanism of Actions

End Users Covered:

  • Hospitals & Clinics
  • Homecare
  • Research Organizations
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Antibiotic Resistance Market, By Disease

  • 5.1 Introduction
  • 5.2 Clostridium difficile infections
  • 5.3 Hospital-acquired bacterial pneumonia
  • 5.4 Complicated intra-abdominal infections
  • 5.5 Community-acquired bacterial pneumonia
  • 5.6 Acute bacterial skin and skin-structure infection
  • 5.7 Bloodstream infection
  • 5.8 Complicated urinary tract infections

6 Global Antibiotic Resistance Market, By Pathogen

  • 6.1 Introduction
  • 6.2 Baumannii
  • 6.3 Pseudomonas aeruginosa
  • 6.4 Enterococcus faecium
  • 6.5 Hemophilus Influenzae
  • 6.6 K. Pneumoniae
  • 6.8 E. Coli
  • 6.9 Streptococcus pneumoniae
  • 6.10 Clostridium difficile
  • 6.11 Staphylococcus Aureus
  • 6.12 Acinetobacter

7 Global Antibiotic Resistance Market, By Drug Class

  • 7.1 Introduction
  • 7.2 Tetracyclines
  • 7.3 Cephalosporins
  • 7.4 Oxazolidinones
  • 7.5 Combination therpaies
  • 7.6 Lipoglycopeptides
  • 7.7 Other Drug Classes

8 Global Antibiotic Resistance Market, By Mechanism of Action

  • 8.1 Introduction
  • 8.2 Cell Wall Synthesis Inhibitors
  • 8.3 DNA Synthesis Inhibitors
  • 8.4 Protein Synthesis Inhibitors
  • 8.5 RNA synthesis inhibitors
  • 8.6 Other Mechanism of ActionS

9 Global Antibiotic Resistance Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Homecare
  • 9.4 Research Organizations
  • 9.5 Other End Users

10 Global Antibiotic Resistance Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Basilea Pharmaceutica Ltd.
  • 12.2 Tetraphase Pharmaceuticals, Inc.
  • 12.3 Entasis therapeutics
  • 12.4 Theravance Biopharma
  • 12.5 Paratek Pharmaceuticals, Inc.
  • 12.6 Seres Therapeutics
  • 12.7 Merck & Co. Inc.
  • 12.8 Achaogen Inc.
  • 12.9 Melinta Therapeutics
  • 12.10 AbbVie, Inc.
  • 12.11 Johnson & Johnson
  • 12.12 Pfizer Inc.
  • 12.13 Cipla Ltd.
  • 12.14 Bayer AG
  • 12.15 AstraZeneca plc
  • 12.16 Novartis AG
  • 12.17 Teva Pharmaceutical Industries Ltd.
  • 12.18 Roche Holding AG
  • 12.19 Cubist Pharmaceuticals, Inc.
  • 12.20 Mylan N.V.

List of Tables

  • Table 1 Global Antibiotic Resistance Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Antibiotic Resistance Market Outlook, By Disease (2021-2030) ($MN)
  • Table 3 Global Antibiotic Resistance Market Outlook, By Clostridium difficile infections (2021-2030) ($MN)
  • Table 4 Global Antibiotic Resistance Market Outlook, By Hospital-acquired bacterial pneumonia (2021-2030) ($MN)
  • Table 5 Global Antibiotic Resistance Market Outlook, By Complicated intra-abdominal infections (2021-2030) ($MN)
  • Table 6 Global Antibiotic Resistance Market Outlook, By Community-acquired bacterial pneumonia (2021-2030) ($MN)
  • Table 7 Global Antibiotic Resistance Market Outlook, By Acute bacterial skin and skin-structure infection (2021-2030) ($MN)
  • Table 8 Global Antibiotic Resistance Market Outlook, By Bloodstream infection (2021-2030) ($MN)
  • Table 9 Global Antibiotic Resistance Market Outlook, By Complicated urinary tract infections (2021-2030) ($MN)
  • Table 10 Global Antibiotic Resistance Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 11 Global Antibiotic Resistance Market Outlook, By Baumannii (2021-2030) ($MN)
  • Table 12 Global Antibiotic Resistance Market Outlook, By Pseudomonas aeruginosa (2021-2030) ($MN)
  • Table 13 Global Antibiotic Resistance Market Outlook, By Enterococcus faecium (2021-2030) ($MN)
  • Table 14 Global Antibiotic Resistance Market Outlook, By Hemophilus Influenzae (2021-2030) ($MN)
  • Table 15 Global Antibiotic Resistance Market Outlook, By K. Pneumoniae (2021-2030) ($MN)
  • Table 16 Global Antibiotic Resistance Market Outlook, By E. Coli (2021-2030) ($MN)
  • Table 17 Global Antibiotic Resistance Market Outlook, By Streptococcus pneumoniae (2021-2030) ($MN)
  • Table 18 Global Antibiotic Resistance Market Outlook, By Clostridium difficile (2021-2030) ($MN)
  • Table 19 Global Antibiotic Resistance Market Outlook, By Staphylococcus Aureus (2021-2030) ($MN)
  • Table 20 Global Antibiotic Resistance Market Outlook, By Acinetobacter (2021-2030) ($MN)
  • Table 21 Global Antibiotic Resistance Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 22 Global Antibiotic Resistance Market Outlook, By Tetracyclines (2021-2030) ($MN)
  • Table 23 Global Antibiotic Resistance Market Outlook, By Cephalosporins (2021-2030) ($MN)
  • Table 24 Global Antibiotic Resistance Market Outlook, By Oxazolidinones (2021-2030) ($MN)
  • Table 25 Global Antibiotic Resistance Market Outlook, By Combination therpaies (2021-2030) ($MN)
  • Table 26 Global Antibiotic Resistance Market Outlook, By Lipoglycopeptides (2021-2030) ($MN)
  • Table 27 Global Antibiotic Resistance Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 28 Global Antibiotic Resistance Market Outlook, By Mechanism of Action (2021-2030) ($MN)
  • Table 29 Global Antibiotic Resistance Market Outlook, By Cell Wall Synthesis Inhibitors (2021-2030) ($MN)
  • Table 30 Global Antibiotic Resistance Market Outlook, By DNA Synthesis Inhibitors (2021-2030) ($MN)
  • Table 31 Global Antibiotic Resistance Market Outlook, By Protein Synthesis Inhibitors (2021-2030) ($MN)
  • Table 32 Global Antibiotic Resistance Market Outlook, By RNA synthesis inhibitors (2021-2030) ($MN)
  • Table 33 Global Antibiotic Resistance Market Outlook, By Other Mechanism of ActionS (2021-2030) ($MN)
  • Table 34 Global Antibiotic Resistance Market Outlook, By End Users (2021-2030) ($MN)
  • Table 35 Global Antibiotic Resistance Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 36 Global Antibiotic Resistance Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 37 Global Antibiotic Resistance Market Outlook, By Research Organizations (2021-2030) ($MN)
  • Table 38 Global Antibiotic Resistance Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.